An old drug offers a new way to stop STIs
Taken after sex, the antibiotic doxycycline can ward off some sexually transmitted illnesses. Doctors are already prescribing it and the CDC is expected to share guidance soon for how best to use it.
Related Articles
Texas measles outbreak nears 650 cases, but fewer than 10 actively infectious
DALLAS — Texas public health officials on Friday reported an additional 22 measles cases in the ongoing outbreak, for a total of 646 outbreak cases.…
H5N1 avian flu strikes more Idaho dairy farms
Over the past few months, Idaho has become the nation’s hot spot for dairy cattle H5N1 detections.
Whooping cough cases rising again in the U.S.
Whooping cough cases are rising, and doctors are bracing for yet another tough year. There have been 8,485 cases reported in 2025, according to preliminary…
Early Vasopressin for Septic Shock: A 16-Year Debate on Its Merits
The VASST trial was first published in 2008 and has spawned 16 years of analysis and debate. Aaron Holley, MD, has vacillated on whether early…
Gilead’s strong HIV business balances out low Covid and cancer drug sales
Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the same amount of…
‘Fighting to breathe’: Whooping cough surges as vaccination rate falters
There have been 8,064 reported cases of whooping cough in the U.S., compared with 3,835 for the same time in 2024, according to CDC data.
USDA withdraws a plan to limit salmonella levels in raw poultry
The Agriculture Department will not require poultry companies to limit salmonella bacteria in their products, halting a Biden Administration effort to prevent food poisoning from…
Whooping cough cases rising again in the U.S.
Whooping cough cases are rising, and doctors are bracing for yet another tough year. There have been 8,485 cases reported in 2025, according to preliminary…
HPV May Be Linked to Thyroid Eye Disease, Small Study Suggests
Immunological link could open up new pathways for treatment, researchers say
Intravenous Immunoglobulin Does Not Improve Clinical Outcomes Compared With Tocilizumab in Severe COVID-19
A study reveals IVIG treatment shows no significant benefits over tocilizumab for severe COVID-19, highlighting higher adverse events and costs.